DGAP-News: Cannovum AG / Key word(s): Product Launch
Cannovum AG (stock exchanges Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has entered into a long term supply agreement with Aurora through its licensed subsidiary, Cannovum Health eG. Starting today, Cannovum will distribute the full range of medical cannabis products offered by Aurora to pharmacies throughout Germany.
The canadian company Aurora is one of the largest authorised manufacturers of medical cannabis in the European Union. After the German legalization of medical cannabis in 2017 Aurora joined the German market with their acquisition of the German company Pedanios, thus making Aurora / Pedanios products one of the first cannabis medicines available in Germany. This allowed doctors and pharmacists to gain experience in treating their patients with these products.
"We want to support doctors and pharmacists in finding the appropriate treatment for their patients. In order for us to achieve that, we need to provide a full portfolio of medical cannabis which gives them the opportunity to fully customize the therapy. By partnering with Aurora we are confident that we continue to provide high quality medication to ensure every patient receives the best therapy", says Pia Marten, CEO of Cannovum AG.
Cannovum's own team of pharmaceutical representatives has received intensive training in the new products, in order to confidently advise pharmacists and doctors.
Linda Rasch, IR & PR, Cannovum AG
For more information, visit www.cannovum.com
24.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
Rheinsberger Str. 76/77
+49 (0)30 3982 16360
Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich
EQS News ID:
End of News
DGAP News Service